Beijing Tiantan Biological Products Corp Ltd (SHG:600161) — Market Cap & Net Worth
Market Cap & Net Worth: Beijing Tiantan Biological Products Corp Ltd (600161)
Beijing Tiantan Biological Products Corp Ltd (SHG:600161) has a market capitalization of $4.11 Billion (CN¥28.06 Billion) as of May 7, 2026. Listed on the SHG stock exchange, this China-based company holds position #4118 globally and #716 in its home market, demonstrating a -4.77% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Beijing Tiantan Biological Products Corp Ltd's stock price CN¥14.19 by its total outstanding shares 1977371446 (1.98 Billion). Analyse cash efficiency ratio of Beijing Tiantan Biological Products Corp to see how efficiently the company converts income to cash.
Beijing Tiantan Biological Products Corp Ltd Market Cap History: 2015 to 2026
Beijing Tiantan Biological Products Corp Ltd's market capitalization history from 2015 to 2026. Data shows growth from $3.35 Billion to $4.11 Billion (3.98% CAGR).
Index Memberships
Beijing Tiantan Biological Products Corp Ltd is a constituent of 1 market index:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
Shanghai Shenzhen CSI 300
CSI300
|
$4.20 Trillion | 0.10% | #157 of 285 |
Weight: Beijing Tiantan Biological Products Corp Ltd's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Beijing Tiantan Biological Products Corp Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Beijing Tiantan Biological Products Corp Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
0.98x
Beijing Tiantan Biological Products Corp Ltd's market cap is 0.98 times its annual revenue
Latest Price to Earnings (P/E) Ratio
3.83x
Beijing Tiantan Biological Products Corp Ltd's market cap is 3.83 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2015 | $3.35 Billion | $1.62 Billion | $9.98 Million | 2.07x | 336.07x |
| 2016 | $3.78 Billion | $2.14 Billion | $256.89 Million | 1.77x | 14.72x |
| 2017 | $3.62 Billion | $2.48 Billion | $1.17 Billion | 1.46x | 3.09x |
| 2018 | $3.51 Billion | $2.93 Billion | $509.48 Million | 1.20x | 6.89x |
| 2019 | $5.55 Billion | $3.28 Billion | $611.09 Million | 1.69x | 9.08x |
| 2020 | $9.96 Billion | $3.45 Billion | $639.01 Million | 2.89x | 15.58x |
| 2021 | $6.94 Billion | $4.11 Billion | $760.01 Million | 1.69x | 9.13x |
| 2022 | $6.85 Billion | $4.26 Billion | $880.92 Million | 1.61x | 7.78x |
| 2023 | $8.95 Billion | $5.18 Billion | $1.11 Billion | 1.73x | 8.07x |
| 2024 | $5.93 Billion | $6.03 Billion | $1.55 Billion | 0.98x | 3.83x |
Competitor Companies of 600161 by Market Capitalization
Companies near Beijing Tiantan Biological Products Corp Ltd in the global market cap rankings as of May 7, 2026.
Key companies related to Beijing Tiantan Biological Products Corp Ltd by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #222 globally with a market cap of $108.50 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #357 globally with a market cap of $74.92 Billion USD.
- UCB SA (BR:UCB): Ranked #513 globally with a market cap of $51.74 Billion USD ( €44.26 Billion EUR).
- argenx NV ADR (NASDAQ:ARGX): Ranked #572 globally with a market cap of $45.97 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #222 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $108.50 Billion | $427.65 |
| #357 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $74.92 Billion | $721.05 |
| #513 | UCB SA | BR:UCB | $51.74 Billion | €236.00 |
| #572 | argenx NV ADR | NASDAQ:ARGX | $45.97 Billion | $787.95 |
Beijing Tiantan Biological Products Corp Ltd Historical Marketcap From 2015 to 2026
Between 2015 and today, Beijing Tiantan Biological Products Corp Ltd's market cap moved from $3.35 Billion to $ 4.11 Billion, with a yearly change of 3.98%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | CN¥4.11 Billion | -13.16% |
| 2025 | CN¥4.73 Billion | -20.29% |
| 2024 | CN¥5.93 Billion | -33.74% |
| 2023 | CN¥8.95 Billion | +30.64% |
| 2022 | CN¥6.85 Billion | -1.19% |
| 2021 | CN¥6.94 Billion | -30.35% |
| 2020 | CN¥9.96 Billion | +79.37% |
| 2019 | CN¥5.55 Billion | +58.13% |
| 2018 | CN¥3.51 Billion | -3.07% |
| 2017 | CN¥3.62 Billion | -4.23% |
| 2016 | CN¥3.78 Billion | +12.80% |
| 2015 | CN¥3.35 Billion | -- |
End of Day Market Cap According to Different Sources
On May 7th, 2026 the market cap of Beijing Tiantan Biological Products Corp Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $4.11 Billion USD |
| MoneyControl | $4.11 Billion USD |
| MarketWatch | $4.11 Billion USD |
| marketcap.company | $4.11 Billion USD |
| Reuters | $4.11 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Beijing Tiantan Biological Products Corp Ltd
Beijing Tiantan Biological Products Co., Ltd. engages in the research and development, manufacture, sale, and marketing of blood products in China and internationlly. Its products include human albumin; intravenous human immunoglobulin; rabies patient immunoglobulin; tetanus human immunoglobulin; hepatitis B human immunoglobulin; freeze-dried intravenous hepatitis B human immunoglobulin; histamin… Read more